These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Kennedy RD; D'Andrea AD Genes Dev; 2005 Dec; 19(24):2925-40. PubMed ID: 16357213 [TBL] [Abstract][Full Text] [Related]
5. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539 [TBL] [Abstract][Full Text] [Related]
6. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells. Yao C; Du W; Chen H; Xiao S; Huang L; Chen F Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439 [TBL] [Abstract][Full Text] [Related]
7. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light. Dunn J; Potter M; Rees A; Rünger TM Cancer Res; 2006 Dec; 66(23):11140-7. PubMed ID: 17145857 [TBL] [Abstract][Full Text] [Related]
8. No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia. Meyer S; White DJ; Will AM; Eden T; Sim A; Brown R; Strathdee G Br J Haematol; 2006 Jul; 134(1):61-3. PubMed ID: 16803569 [TBL] [Abstract][Full Text] [Related]
9. The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Mirchandani KD; D'Andrea AD Exp Cell Res; 2006 Aug; 312(14):2647-53. PubMed ID: 16859679 [TBL] [Abstract][Full Text] [Related]
10. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Martinez A; Hinz JM; Gómez L; Molina B; Acuña H; Jones IM; Frias S; Coleman MA Mutat Res; 2008 Oct; 656(1-2):1-7. PubMed ID: 18647660 [TBL] [Abstract][Full Text] [Related]
11. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635 [TBL] [Abstract][Full Text] [Related]
12. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2. Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527 [TBL] [Abstract][Full Text] [Related]
14. Fancf-deficient mice are prone to develop ovarian tumours. Bakker ST; van de Vrugt HJ; Visser JA; Delzenne-Goette E; van der Wal A; Berns MA; van de Ven M; Oostra AB; de Vries S; Kramer P; Arwert F; van der Valk M; de Winter JP; te Riele H J Pathol; 2012 Jan; 226(1):28-39. PubMed ID: 21915857 [TBL] [Abstract][Full Text] [Related]
16. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Gallmeier E; Kern SE Clin Cancer Res; 2007 Jan; 13(1):4-10. PubMed ID: 17200332 [TBL] [Abstract][Full Text] [Related]
17. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Soulier J; Leblanc T; Larghero J; Dastot H; Shimamura A; Guardiola P; Esperou H; Ferry C; Jubert C; Feugeas JP; Henri A; Toubert A; Socié G; Baruchel A; Sigaux F; D'Andrea AD; Gluckman E Blood; 2005 Feb; 105(3):1329-36. PubMed ID: 15383454 [TBL] [Abstract][Full Text] [Related]
18. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. D'Andrea AD Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475 [TBL] [Abstract][Full Text] [Related]
19. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532 [TBL] [Abstract][Full Text] [Related]
20. The genetic and molecular basis of Fanconi anemia. de Winter JP; Joenje H Mutat Res; 2009 Jul; 668(1-2):11-9. PubMed ID: 19061902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]